CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 55 enrolled
Drug / intervention
LAS190792 Dose 1 +10 moredrug
Likely dose
Tiotropium 18 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02059434
NCT02059434Phase 1Completed
CompareCT.gov

A 2-Part, Randomised, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Study Of LAS190792 Delivered By Inhalation In Asthmatic And Chronic Obstructive Pulmonary Disease (COPD) Subjects

AstraZeneca·interventional·Posted Feb 11, 2014·Updated Jun 21, 2019

In Brief

A Phase 1 clinical trial evaluating LAS190792 Dose 1, LAS190792 Dose 2, and 9 other interventions for Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Completed, enrolled 55 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess the safety and tolerability of single doses of LAS190792 administered by inhalation to patients with mild persistent asthma and moderate to severe chronic obstructive pulmonary disease (COPD) and also to assess the ability of LAS190792 to produce bronchodilation (opening of the airways).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD), Asthma
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2014
Enrollment StartSep 1, 2013
Primary CompletionOct 6, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.4 years ago

Interventions

LAS190792 Dose 1drug

LAS190792 Dose 2drug

LAS190792 Dose 3drug

LAS190792 Dose 4drug

LAS190792 Dose 5drug

LAS190792 Dose 6drug

LAS190792 Dose 1 (Part 2)drug

LAS190792 Dose 2 (Part 2)drug

Tiotropium 18 μgdrug

Indacaterol 150 μgdrug

Placebodrug